Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Nephrol ; 33(3): 269-76, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21372562

RESUMO

BACKGROUND/AIMS: Contrast-induced nephropathy (CIN) remains a leading cause of iatrogenic acute renal failure. Terlipressin, a long-acting analog of vasopressin, may improve renal function. This study aimed to investigate the possible protective effect of terlipressin against the development of experimental CIN in rats. METHODS: Wistar albino rats (n = 32) were allocated randomly into four equal groups of 8 each, i.e. control, terlipressin, contrast media (CM), and terlipressin plus contrast media (TCM). CIN was induced by intravenous administration of indomethacin (10 mg/kg), N-nitro L-arginine methyl ester (L-NAME, 10 mg/kg, twice at 15 and 30 min), and high-osmolar contrast media meglumine amidotrizoate 60%. Renal function parameters, kidney histology, and tubular expression of vascular endothelial growth factor (VEGF) were determined. RESULTS: Mean serum creatinine levels were decreased (p < 0.05) and creatinine clearance (p < 0.05) increased in the TCM group compared with the CM group. Notably, rats in the TCM group displayed less tubular necrosis (p < 0.05), medullary congestion (p < 0.05), and a reduced tubular expression of VEGF (p < 0.05) compared with the CM group. CONCLUSION: These results demonstrate that terlipressin can inhibit the development of CIN.


Assuntos
Injúria Renal Aguda/induzido quimicamente , Meios de Contraste/efeitos adversos , Lipressina/análogos & derivados , Vasoconstritores/uso terapêutico , Vasopressinas/agonistas , Injúria Renal Aguda/prevenção & controle , Animais , Modelos Animais de Doenças , Testes de Função Renal , Lipressina/uso terapêutico , Ratos , Ratos Endogâmicos BB , Terlipressina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...